vs
ICU MEDICAL INC（ICUI）与W. P. Carey Inc.（WPC）财务数据对比。点击上方公司名可切换其他公司
ICU MEDICAL INC的季度营收约是W. P. Carey Inc.的1.2倍（$540.7M vs $444.5M），W. P. Carey Inc.净利率更高（33.4% vs -2.9%，领先36.3%），W. P. Carey Inc.同比增速更快（9.4% vs -14.1%），过去两年W. P. Carey Inc.的营收复合增速更高（6.8% vs -2.3%）
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
W.P.凯里是一家房地产投资信托企业，主打投资以三净租赁模式租予单一租户的物业。公司注册地位于美国马里兰州，核心办公地点设在纽约市，深耕商业地产投资领域，拥有成熟的运营经验与优质的项目资源。
ICUI vs WPC — 直观对比
营收规模更大
ICUI
是对方的1.2倍
$444.5M
营收增速更快
WPC
高出23.6%
-14.1%
净利率更高
WPC
高出36.3%
-2.9%
两年增速更快
WPC
近两年复合增速
-2.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $540.7M | $444.5M |
| 净利润 | $-15.7M | $148.3M |
| 毛利率 | 37.5% | — |
| 营业利润率 | 1.0% | 34.5% |
| 净利率 | -2.9% | 33.4% |
| 营收同比 | -14.1% | 9.4% |
| 净利润同比 | 34.0% | 215.4% |
| 每股收益（稀释后） | $-0.63 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICUIWPC
| Q4 25 | $540.7M | $444.5M | ||
| Q3 25 | $537.0M | $431.3M | ||
| Q2 25 | $548.9M | $430.8M | ||
| Q1 25 | $604.7M | $409.9M | ||
| Q4 24 | $629.8M | $406.2M | ||
| Q3 24 | $589.1M | $397.4M | ||
| Q2 24 | $596.5M | $389.7M | ||
| Q1 24 | $566.7M | $389.8M |
净利润ICUIWPC
| Q4 25 | $-15.7M | $148.3M | ||
| Q3 25 | $-3.4M | $141.0M | ||
| Q2 25 | $35.3M | $51.2M | ||
| Q1 25 | $-15.5M | $125.8M | ||
| Q4 24 | $-23.8M | $47.0M | ||
| Q3 24 | $-33.0M | $111.7M | ||
| Q2 24 | $-21.4M | $142.9M | ||
| Q1 24 | $-39.5M | $159.2M |
毛利率ICUIWPC
| Q4 25 | 37.5% | — | ||
| Q3 25 | 37.4% | — | ||
| Q2 25 | 37.9% | — | ||
| Q1 25 | 34.7% | — | ||
| Q4 24 | 36.1% | — | ||
| Q3 24 | 34.8% | — | ||
| Q2 24 | 34.8% | — | ||
| Q1 24 | 32.7% | — |
营业利润率ICUIWPC
| Q4 25 | 1.0% | 34.5% | ||
| Q3 25 | 2.6% | 34.7% | ||
| Q2 25 | 1.9% | 15.0% | ||
| Q1 25 | 2.1% | 33.5% | ||
| Q4 24 | 6.0% | 13.5% | ||
| Q3 24 | 1.4% | 30.4% | ||
| Q2 24 | 1.3% | 38.3% | ||
| Q1 24 | -1.9% | 43.0% |
净利率ICUIWPC
| Q4 25 | -2.9% | 33.4% | ||
| Q3 25 | -0.6% | 32.7% | ||
| Q2 25 | 6.4% | 11.9% | ||
| Q1 25 | -2.6% | 30.7% | ||
| Q4 24 | -3.8% | 11.6% | ||
| Q3 24 | -5.6% | 28.1% | ||
| Q2 24 | -3.6% | 36.7% | ||
| Q1 24 | -7.0% | 40.8% |
每股收益（稀释后）ICUIWPC
| Q4 25 | $-0.63 | — | ||
| Q3 25 | $-0.14 | — | ||
| Q2 25 | $1.43 | — | ||
| Q1 25 | $-0.63 | — | ||
| Q4 24 | $-0.97 | — | ||
| Q3 24 | $-1.35 | — | ||
| Q2 24 | $-0.88 | — | ||
| Q1 24 | $-1.63 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $155.3M |
| 总债务越低越好 | — | $8.7B |
| 股东权益账面价值 | $2.1B | $8.1B |
| 总资产 | $4.1B | $18.0B |
| 负债/权益比越低杠杆越低 | — | 1.07× |
8季度趋势，按日历期对齐
现金及短期投资ICUIWPC
| Q4 25 | — | $155.3M | ||
| Q3 25 | — | $249.0M | ||
| Q2 25 | — | $244.8M | ||
| Q1 25 | — | $187.8M | ||
| Q4 24 | $308.6M | $640.4M | ||
| Q3 24 | $312.5M | $818.2M | ||
| Q2 24 | $302.6M | $1.1B | ||
| Q1 24 | $251.4M | $777.0M |
总债务ICUIWPC
| Q4 25 | — | $8.7B | ||
| Q3 25 | — | $8.7B | ||
| Q2 25 | — | $8.6B | ||
| Q1 25 | — | $7.9B | ||
| Q4 24 | — | $8.0B | ||
| Q3 24 | — | $8.0B | ||
| Q2 24 | — | $8.1B | ||
| Q1 24 | — | $7.9B |
股东权益ICUIWPC
| Q4 25 | $2.1B | $8.1B | ||
| Q3 25 | $2.1B | $8.2B | ||
| Q2 25 | $2.1B | $8.2B | ||
| Q1 25 | $2.0B | $8.4B | ||
| Q4 24 | $2.0B | $8.4B | ||
| Q3 24 | $2.0B | $8.6B | ||
| Q2 24 | $2.0B | $8.6B | ||
| Q1 24 | $2.1B | $8.7B |
总资产ICUIWPC
| Q4 25 | $4.1B | $18.0B | ||
| Q3 25 | $4.1B | $18.0B | ||
| Q2 25 | $4.1B | $18.0B | ||
| Q1 25 | $4.2B | $17.3B | ||
| Q4 24 | $4.2B | $17.5B | ||
| Q3 24 | $4.3B | $17.6B | ||
| Q2 24 | $4.3B | $17.8B | ||
| Q1 24 | $4.3B | $17.6B |
负债/权益比ICUIWPC
| Q4 25 | — | 1.07× | ||
| Q3 25 | — | 1.06× | ||
| Q2 25 | — | 1.05× | ||
| Q1 25 | — | 0.94× | ||
| Q4 24 | — | 0.95× | ||
| Q3 24 | — | 0.93× | ||
| Q2 24 | — | 0.94× | ||
| Q1 24 | — | 0.91× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.6M | $304.6M |
| 自由现金流经营现金流 - 资本支出 | $36.0M | — |
| 自由现金流率自由现金流/营收 | 6.6% | — |
| 资本支出强度资本支出/营收 | 4.6% | — |
| 现金转化率经营现金流/净利润 | — | 2.05× |
| 过去12个月自由现金流最近4个季度 | $91.8M | — |
8季度趋势，按日历期对齐
经营现金流ICUIWPC
| Q4 25 | $60.6M | $304.6M | ||
| Q3 25 | $56.7M | $300.5M | ||
| Q2 25 | $11.2M | $404.0M | ||
| Q1 25 | $51.3M | $273.2M | ||
| Q4 24 | $40.2M | $296.3M | ||
| Q3 24 | $36.1M | $280.2M | ||
| Q2 24 | $82.0M | $221.0M | ||
| Q1 24 | $45.8M | $1.0B |
自由现金流ICUIWPC
| Q4 25 | $36.0M | — | ||
| Q3 25 | $27.6M | — | ||
| Q2 25 | $-8.5M | — | ||
| Q1 25 | $36.7M | — | ||
| Q4 24 | $16.1M | — | ||
| Q3 24 | $16.2M | — | ||
| Q2 24 | $62.5M | — | ||
| Q1 24 | $29.9M | — |
自由现金流率ICUIWPC
| Q4 25 | 6.6% | — | ||
| Q3 25 | 5.1% | — | ||
| Q2 25 | -1.5% | — | ||
| Q1 25 | 6.1% | — | ||
| Q4 24 | 2.6% | — | ||
| Q3 24 | 2.7% | — | ||
| Q2 24 | 10.5% | — | ||
| Q1 24 | 5.3% | — |
资本支出强度ICUIWPC
| Q4 25 | 4.6% | — | ||
| Q3 25 | 5.4% | — | ||
| Q2 25 | 3.6% | — | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 3.8% | — | ||
| Q3 24 | 3.4% | — | ||
| Q2 24 | 3.3% | — | ||
| Q1 24 | 2.8% | — |
现金转化率ICUIWPC
| Q4 25 | — | 2.05× | ||
| Q3 25 | — | 2.13× | ||
| Q2 25 | 0.32× | 7.89× | ||
| Q1 25 | — | 2.17× | ||
| Q4 24 | — | 6.30× | ||
| Q3 24 | — | 2.51× | ||
| Q2 24 | — | 1.55× | ||
| Q1 24 | — | 6.50× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
WPC
暂无分部数据
